Hydralazine-induced antineutrophil cytoplasmic antibody-associated vasculitis with pulmonary–renal syndrome: a case report
Authors:
Open Access
- 15 April 2020
- journal article
- case report
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 14 (1) , 1-5
Abstract
Background: Hydralazine is a common vasodilator which has been used for the treatment of hypertension and heart failure. Hydralazine can induce antineutrophil cytoplasmic antibody-associated vasculitis due to its auto-immunogenic capability and one of the very rare presentations is pulmonary–renal syndrome. Case presentation: We report a case of a 64-year-old African American woman, who presented to our emergency room with shortness of breath, orthopnea, paroxysmal nocturnal dyspnea, leg swelling, fatigue, loss of appetite, cough with clear sputum, and lightheadedness. On admission, she developed acute hypoxic respiratory failure requiring intubation and acute renal failure requiring hemodialysis. A serologic workup was positive for antineutrophil cytoplasmic antibody, antinuclear antibody, anti-histone, anti-cardiolipin IgM, and anti-double-stranded DNA antibodies. A renal biopsy was done due to persistent deterioration in kidney function and demonstrated classic crescentic (pauci-immune) glomerulonephritis. Hydralazine was empirically discontinued early in the admission and she was started on corticosteroids and cyclophosphamide following biopsy results. She was clinically stable but remained dependent on hemodialysis after discharge. Conclusion: Hydralazine-induced antineutrophil cytoplasmic antibody-associated vasculitis with pulmonary–renal syndrome is a rare occurrence. In the setting of hydralazine use, multiple positive antigens, and multisystem involvement, clinicians should consider this rare condition requiring prompt cessation of offending drug, early evaluation with biopsy, and contemplate empiric immunosuppressive therapy while biopsy confirmation is pending.Keywords
This publication has 16 references indexed in Scilit:
- Hydralazine and nitrates alone or combined for the management of chronic heart failure: A systematic reviewInternational Journal of Cardiology, 2015
- Hydralazine Associated Pauci-Immune GlomerulonephritisJCR: Journal of Clinical Rheumatology, 2014
- Trojan horsesCurrent Opinion in Rheumatology, 2014
- Hydralazine for essential hypertensionCochrane Database of Systematic Reviews, 2011
- Hydralazine-induced autoimmune disease: comparison to idiopathic lupus and ANCA-positive vasculitisModern Rheumatology, 2009
- Association between thyroid disease and its treatment with ANCA small-vessel vasculitis: a case control studyNephrology Dialysis Transplantation, 2007
- Hydralazine may induce autoimmunity by inhibiting extracellular signal–regulated kinase pathway signalingArthritis & Rheumatism, 2003
- Autoantibodies to leucocyte antigens in hydralazine‐associated nephritisJournal of Internal Medicine, 1992
- Hydralazine‐associated GlomerulonephritisActa Medica Scandinavica, 1985
- A method for estimating the probability of adverse drug reactionsClinical Pharmacology & Therapeutics, 1981